Chemistry:Tiomolibdic acid

From HandWiki
Short description: Chemical compound
Tiomolibdic acid
Tiomolibdic acid.svg
Clinical data
Trade namesDecuprate
Other namesTetrathiomolybdic acid; choline salt: ATN-224, WTX101, ALXN1840
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaH2MoS4
Molar mass226.21 g·mol−1
3D model (JSmol)

Tiomolibdic acid (trade name Decuprate) is a chelating agent under investigation for the treatment of cancer and of Wilson's disease,[1] a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate.

Wilson's disease is an autosomal recessive genetic disorder that is manifested by serious hepatic, neurologic or psychiatric symptoms. The disease is fatal if left untreated. It is estimated that 1 individual in every 30,000 to 100,000 worldwide has Wilson's disease.[2]

Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer[3][4][5] and has received orphan designation in the US and EU as a potential therapy against Wilson's disease.[6][7]

Pharmacology

Mechanism of action

Tiomolibdic acid selectively forms highly stable complexes with copper and proteins. These complexes are then believed to be primarily excreted via the bile, restoring the normal excretion route of copper that is impaired in patients with Wilson's disease.[8][9][10]

The binding and excretion mechanism is stable; whereas many de-coppering agents form unstable complexes that are excreted via urine.[11]

Bis-choline tetrathiomolybdate

Clinical trials

As of November 2014, a Phase 2, multi-centre, open-label study was recruiting newly diagnosed Wilson's disease patients 18 and older to evaluate the efficacy and safety of bis-choline tetrathiomolybdate administration over a 24-week period.[12][13]

As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology[3][4][5][14][15][16][17][18][19][20] and Wilson's disease,[21][22][23][24] as well as some other clinical pathologies.[25][26]

The data suggest that bis-choline tetrathiomolybdate can rapidly lower and control toxic free copper levels and improve clinical symptoms in Wilson's disease patients. The data also suggest that it is generally well tolerated, with the potential for a reduced risk of neurological worsening after initiation of therapy compared to existing therapies.[22][23][24]

Dosing

Previous clinical studies with bis-choline tetrathiomolybdate in oncology patients have shown that it can lower and maintain copper levels using a once or twice daily oral dosing.[4][5] This may be helpful since untreated Wilson's disease may lead to death within several years of the onset of symptoms,[27] and medication use should continue throughout the patient's lifespan. Patient compliance is crucial for clinical improvement, and it is a particular challenge for Wilson's disease patients taking de-coppering treatments.[28]

Society and culture

Names

Tiomolibdic acid is the recommended International nonproprietary name (INN).[29]

References

  1. ↑ "Tiomolibdic acid". https://drugs.ncats.io/substance/206J6X63BE.  This article incorporates text from this source, which is in the public domain.
  2. ↑ "Wilson's disease". Lancet 369 (9559): 397–408. February 2007. doi:10.1016/S0140-6736(07)60196-2. PMID 17276780. 
  3. ↑ 3.0 3.1 "Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting". Blood 108: Abstract 2593. 2006. 
  4. ↑ 4.0 4.1 4.2 "A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer". Urologic Oncology 31 (5): 581–8. July 2013. doi:10.1016/j.urolonc.2011.04.009. PMID 21816640. 
  5. ↑ 5.0 5.1 5.2 "Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors". Clinical Cancer Research 14 (22): 7526–34. November 2008. doi:10.1158/1078-0432.CCR-08-0315. PMID 19010871. 
  6. ↑ Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease, EMA/COMP/795268/2012, ATN-224, 18 February 2013.
  7. ↑ Orphan Drug Designations and Approvals: choline tetrathiomolybdate, U.S. Food and Drug Administration, 25 August 2011
  8. ↑ "Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats". Chemico-Biological Interactions 124 (3): 217–31. February 2000. doi:10.1016/s0009-2797(99)00159-3. PMID 10728780. 
  9. ↑ "A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy". Journal of Inorganic Biochemistry 41 (2): 87–92. February 1991. doi:10.1016/0162-0134(91)80002-y. PMID 2033396. 
  10. ↑ "Systemic dispositions of molybdenum and copper after tetrathiomolybdate injection in LEC rats". Journal of Trace Elements in Medicine and Biology 9 (3): 165–9. October 1995. doi:10.1016/S0946-672X(11)80042-8. PMID 8605606. 
  11. ↑ "Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines". Journal of Inorganic Biochemistry 123: 80–7. June 2013. doi:10.1016/j.jinorgbio.2013.02.011. PMID 23563391. 
  12. ↑ Clinical trial number NCT02273596 for "Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients" at ClinicalTrials.gov
  13. ↑ "Wilson Disease Clinical Trials. Phase 2 Study in Newly Diagnosed Wilson Disease Patients with WTX101 (Tetrathiomolybdate)". Wilson Disease Association. 2009. http://www.wilsonsdisease.org/wilson-disease-research/wilsondisease-clinicaltrials.php. 
  14. ↑ "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study". Clinical Cancer Research 6 (1): 1–10. January 2000. PMID 10656425. 
  15. ↑ "A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer". Investigational New Drugs 27 (2): 159–65. April 2009. doi:10.1007/s10637-008-9165-9. PMID 18712502. 
  16. ↑ "Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer". Oncology 71 (3–4): 168–75. 2006. doi:10.1159/000106066. PMID 17641535. 
  17. ↑ "Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse". Annals of Oncology 24 (6): 1491–8. June 2013. doi:10.1093/annonc/mds654. PMID 23406736. 
  18. ↑ "A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results". The Annals of Thoracic Surgery 86 (2): 383–9; discussion 390. August 2008. doi:10.1016/j.athoracsur.2008.03.016. PMID 18640301. 
  19. ↑ "Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer". Clinical Cancer Research 9 (5): 1666–72. May 2003. PMID 12738719. 
  20. ↑ "Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer". Investigational New Drugs 31 (2): 435–42. April 2013. doi:10.1007/s10637-012-9864-0. PMID 22847786. 
  21. ↑ "Diagnosis and treatment of Wilson disease: an update". Hepatology 47 (6): 2089–111. June 2008. doi:10.1002/hep.22261. PMID 18506894. 
  22. ↑ 22.0 22.1 "Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research 154 (2): 70–7. August 2009. doi:10.1016/j.trsl.2009.05.002. PMID 19595438. 
  23. ↑ 23.0 23.1 "Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease". Archives of Neurology 63 (4): 521–7. April 2006. doi:10.1001/archneur.63.4.521. PMID 16606763. 
  24. ↑ 24.0 24.1 "Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy". Archives of Neurology 60 (3): 379–85. March 2003. doi:10.1001/archneur.60.3.379. PMID 12633149. 
  25. ↑ "Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial". Translational Research 155 (3): 123–30. March 2010. doi:10.1016/j.trsl.2009.09.009. PMID 20171597. 
  26. ↑ "Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration". Transactions of the American Ophthalmological Society 100: 73–6; discussion 76-7. 2002. PMID 12545680. 
  27. ↑ "Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period". Journal of Neurology 252 (6): 698–703. June 2005. doi:10.1007/s00415-005-0720-4. PMID 15742108. 
  28. ↑ "Persistence with treatment in patients with Wilson disease". Neurologia I Neurochirurgia Polska 44 (3): 260–3. 2010. doi:10.1016/s0028-3843(14)60040-2. PMID 20625962. https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/60607. 
  29. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 63". WHO Drug Information 24 (1). 2010. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Tiomolibdic_acid&oldid=3330668"